K562 Artificial Antigen Presenting Cells

K562 artificial antigen-presenting cells (aAPCs) are engineered derivatives of the human K562 cell line that mimic key functions of professional antigen-presenting cells for controlled T-cell stimulation. By expressing selected peptide–major histocompatibility complex (MHC) molecules, costimulatory ligands, and, when needed, cytokines, they engage T-cell receptors and provide signals that promote activation, proliferation, and functional differentiation. In immunology and infection research, K562 aAPCs support the expansion and analysis of antigen-specific T cells without requiring primary antigen-presenting cells from donors. Their defined components improve experimental consistency and enable studies of cellular immunity, immune therapies, and responses to infectious antigens.

K562 Artificial Antigen Presenting Cells - Related Videos

Research

JoVE Journal - Immunology and Infection
Free Sample

Artificial Antigen Presenting Cell (aAPC) Mediated Activation and Expansion of Natural Killer T Cells

0 Views •

Cited by 20 •

2012

Here we describe a method for activating and expanding human NKT cells from bulk T cell populations using artificial antigen presenting cells (aAPC). The use of CD1d-based aAPC provides a standardized method for generating high numbers of functional NKT cells.

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

0 Views •

Cited by 53 •

2013

T cells expressing a CD19-specific chimeric antigen receptor (CAR) are infused as investigational treatment of B-cell malignancies in our first-in-human gene therapy trials. We describe genetic modification of T cells using the Sleeping Beauty (SB) system to introduce CD19-specific CAR and selective propagation on designer CD19+ artificial antigen presenting cells.

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

0 Views •

Cited by 17 •

2011

A new DC independent method for induction and expansion of antigen-specific T cells is described. HLA A2-Ig based artificial Antigen Presenting Cells (aAPC) are loaded with HLA-A2 restricted peptides to efficiently expand CTL of diverse antigen specificity. This technology holds great potential for CTL-based adoptive immunotherapy.

Research

JoVE EoE - Immune Response

Killing K562 Cells by Peripheral Blood Mononuclear Cells Exposed to Tobacco Product Preparations

0 Views •

2025

In this video, we study the effect of a whole smoke-conditioned medium, a combustible tobacco product preparation, on K562 cell killing by effector peripheral blood mononuclear cells.

Killer Artificial Antigen Presenting Cells (KaAPC) for Efficient In Vitro Depletion of Human Antigen-specific T Cells

0 Views •

Cited by 7 •

2014

Guidelines are presented for the generation of killer artificial antigen presenting cells, KaAPC, an efficient tool for in vitro depletion of human antigen-specific T cells and an alternative solution to cellular immunotherapy for the treatment of T cell-mediated autoimmune diseases in an antigen-specific fashion without compromising the remaining immune system.

View All Results

FAQs

Related Topics